Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Neoplasms | 79 | 2024 | 2360 | 10.610 |
Why?
|
Quinolines | 15 | 2024 | 769 | 4.600 |
Why?
|
Phenylurea Compounds | 17 | 2024 | 532 | 4.560 |
Why?
|
Proto-Oncogene Proteins c-ret | 18 | 2024 | 228 | 4.350 |
Why?
|
Iodine Radioisotopes | 26 | 2024 | 1035 | 3.800 |
Why?
|
Carcinoma, Neuroendocrine | 17 | 2024 | 342 | 3.690 |
Why?
|
Head and Neck Neoplasms | 44 | 2024 | 2915 | 2.640 |
Why?
|
Protein Kinase Inhibitors | 32 | 2024 | 5709 | 2.500 |
Why?
|
Pyrazoles | 15 | 2024 | 2024 | 2.190 |
Why?
|
Carcinoma, Squamous Cell | 39 | 2019 | 4083 | 2.060 |
Why?
|
Pyridines | 20 | 2024 | 2888 | 1.810 |
Why?
|
Radiation Tolerance | 9 | 2021 | 478 | 1.720 |
Why?
|
Oncogene Proteins, Fusion | 6 | 2024 | 1614 | 1.630 |
Why?
|
Antineoplastic Agents | 42 | 2024 | 13708 | 1.580 |
Why?
|
Proto-Oncogene Proteins B-raf | 12 | 2022 | 2072 | 1.330 |
Why?
|
Carcinoma | 9 | 2020 | 2341 | 1.210 |
Why?
|
Anilides | 9 | 2024 | 415 | 1.140 |
Why?
|
Oropharyngeal Neoplasms | 5 | 2022 | 493 | 1.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 28 | 2024 | 11843 | 1.080 |
Why?
|
Carcinoma, Papillary | 9 | 2022 | 792 | 1.050 |
Why?
|
Receptor, trkA | 6 | 2024 | 159 | 0.920 |
Why?
|
Indazoles | 2 | 2024 | 306 | 0.910 |
Why?
|
Adenoma, Oxyphilic | 4 | 2024 | 152 | 0.900 |
Why?
|
Lung Neoplasms | 14 | 2024 | 13589 | 0.900 |
Why?
|
Papillomavirus Infections | 8 | 2022 | 1638 | 0.870 |
Why?
|
Carcinoma, Medullary | 6 | 2023 | 116 | 0.870 |
Why?
|
Neoplasms, Squamous Cell | 4 | 2012 | 96 | 0.860 |
Why?
|
Molecular Targeted Therapy | 8 | 2021 | 2834 | 0.850 |
Why?
|
Adenocarcinoma, Follicular | 4 | 2024 | 325 | 0.790 |
Why?
|
Adenocarcinoma | 7 | 2024 | 6400 | 0.740 |
Why?
|
Quinazolines | 8 | 2024 | 1376 | 0.710 |
Why?
|
Mutation | 26 | 2024 | 30243 | 0.660 |
Why?
|
Papillomaviridae | 5 | 2022 | 1135 | 0.660 |
Why?
|
Lymphocyte Count | 1 | 2021 | 793 | 0.630 |
Why?
|
Neoplasm Metastasis | 17 | 2024 | 4931 | 0.620 |
Why?
|
Mouth Neoplasms | 3 | 2017 | 598 | 0.600 |
Why?
|
Thyroid Nodule | 4 | 2021 | 766 | 0.570 |
Why?
|
Pyrimidines | 5 | 2024 | 3050 | 0.570 |
Why?
|
Leukocyte Count | 1 | 2021 | 1604 | 0.560 |
Why?
|
Carcinoma, Adenoid Cystic | 5 | 2024 | 264 | 0.540 |
Why?
|
Thyroid Gland | 5 | 2023 | 1172 | 0.530 |
Why?
|
Humans | 169 | 2024 | 768451 | 0.510 |
Why?
|
Sulfonamides | 4 | 2016 | 1988 | 0.480 |
Why?
|
Indoles | 6 | 2016 | 1834 | 0.480 |
Why?
|
Gene Fusion | 4 | 2023 | 356 | 0.480 |
Why?
|
Respiratory Rate | 1 | 2016 | 180 | 0.470 |
Why?
|
Cell Differentiation | 6 | 2024 | 11674 | 0.460 |
Why?
|
Niacinamide | 6 | 2015 | 419 | 0.460 |
Why?
|
Thyroidectomy | 10 | 2024 | 915 | 0.460 |
Why?
|
Combined Modality Therapy | 21 | 2021 | 8559 | 0.450 |
Why?
|
Neoplasm Recurrence, Local | 12 | 2024 | 9425 | 0.430 |
Why?
|
Carboplatin | 10 | 2024 | 798 | 0.420 |
Why?
|
Aged | 68 | 2024 | 171520 | 0.400 |
Why?
|
Genes, Neoplasm | 1 | 2014 | 370 | 0.400 |
Why?
|
Infratentorial Neoplasms | 1 | 2012 | 99 | 0.380 |
Why?
|
Chemoprevention | 1 | 2014 | 326 | 0.380 |
Why?
|
Treatment Outcome | 37 | 2024 | 65409 | 0.370 |
Why?
|
Acoustic Stimulation | 1 | 2016 | 1253 | 0.370 |
Why?
|
Middle Aged | 76 | 2024 | 223418 | 0.370 |
Why?
|
Pyrroles | 3 | 2014 | 1127 | 0.360 |
Why?
|
Clinical Trials as Topic | 7 | 2019 | 8051 | 0.360 |
Why?
|
Male | 89 | 2024 | 364781 | 0.360 |
Why?
|
Salivary Gland Neoplasms | 3 | 2021 | 306 | 0.350 |
Why?
|
Gene Rearrangement | 3 | 2021 | 1139 | 0.340 |
Why?
|
Paranasal Sinuses | 1 | 2012 | 266 | 0.340 |
Why?
|
Female | 90 | 2024 | 396943 | 0.330 |
Why?
|
Double-Blind Method | 13 | 2024 | 12450 | 0.330 |
Why?
|
Taxoids | 9 | 2016 | 669 | 0.320 |
Why?
|
Carcinoid Tumor | 2 | 2014 | 226 | 0.310 |
Why?
|
Neutrophils | 1 | 2021 | 3790 | 0.300 |
Why?
|
Monitoring, Physiologic | 1 | 2016 | 1795 | 0.300 |
Why?
|
Aged, 80 and over | 29 | 2024 | 59680 | 0.290 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2024 | 5342 | 0.280 |
Why?
|
Adult | 57 | 2024 | 223542 | 0.270 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 4 | 2017 | 665 | 0.270 |
Why?
|
Benzamides | 2 | 2024 | 1381 | 0.270 |
Why?
|
Carcinoma, Ductal | 2 | 2020 | 97 | 0.270 |
Why?
|
Kaplan-Meier Estimate | 10 | 2020 | 6537 | 0.270 |
Why?
|
Imidazoles | 3 | 2020 | 1174 | 0.270 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2006 | 90 | 0.260 |
Why?
|
Infant, Premature | 1 | 2016 | 2124 | 0.260 |
Why?
|
Piperidines | 5 | 2024 | 1664 | 0.260 |
Why?
|
Proto-Oncogene Proteins c-met | 3 | 2020 | 568 | 0.250 |
Why?
|
Radiotherapy, Intensity-Modulated | 5 | 2015 | 811 | 0.250 |
Why?
|
Tumor Burden | 2 | 2022 | 1909 | 0.250 |
Why?
|
Neoplasms | 10 | 2023 | 22386 | 0.250 |
Why?
|
Neoadjuvant Therapy | 3 | 2024 | 2896 | 0.240 |
Why?
|
Medical Oncology | 6 | 2022 | 2347 | 0.230 |
Why?
|
Herpesvirus 4, Human | 3 | 2024 | 1081 | 0.230 |
Why?
|
Heart Rate | 1 | 2016 | 4218 | 0.230 |
Why?
|
Nasopharyngeal Neoplasms | 3 | 2024 | 290 | 0.230 |
Why?
|
Disease-Free Survival | 15 | 2018 | 6856 | 0.230 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2024 | 1797 | 0.230 |
Why?
|
Diarrhea | 3 | 2022 | 1320 | 0.220 |
Why?
|
Laryngeal Neoplasms | 3 | 2018 | 515 | 0.220 |
Why?
|
Disease Management | 3 | 2024 | 2533 | 0.200 |
Why?
|
Aphasia | 1 | 2024 | 193 | 0.200 |
Why?
|
Chylous Ascites | 1 | 2022 | 21 | 0.200 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 1104 | 0.200 |
Why?
|
Recurrent Laryngeal Nerve | 1 | 2024 | 145 | 0.200 |
Why?
|
Neoplasm Proteins | 2 | 2014 | 3611 | 0.200 |
Why?
|
Survival Rate | 11 | 2021 | 12875 | 0.190 |
Why?
|
Cisplatin | 9 | 2016 | 1661 | 0.190 |
Why?
|
Phosphotransferases | 2 | 2021 | 303 | 0.190 |
Why?
|
Maximum Tolerated Dose | 5 | 2020 | 890 | 0.190 |
Why?
|
Chylothorax | 1 | 2022 | 83 | 0.190 |
Why?
|
Hypertension | 2 | 2020 | 8611 | 0.190 |
Why?
|
Precancerous Conditions | 1 | 2008 | 988 | 0.190 |
Why?
|
Neoplasm Staging | 17 | 2024 | 11249 | 0.190 |
Why?
|
Radiotherapy, Adjuvant | 7 | 2015 | 1794 | 0.190 |
Why?
|
Oncogene Fusion | 1 | 2021 | 83 | 0.190 |
Why?
|
Salvage Therapy | 3 | 2017 | 1277 | 0.180 |
Why?
|
Nuclear Receptor Coactivators | 1 | 2021 | 60 | 0.180 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2023 | 2434 | 0.180 |
Why?
|
Papillomavirus Vaccines | 2 | 2019 | 497 | 0.180 |
Why?
|
Calcitonin | 4 | 2019 | 329 | 0.180 |
Why?
|
Thyroglobulin | 4 | 2014 | 111 | 0.180 |
Why?
|
Vocal Cord Paralysis | 1 | 2024 | 275 | 0.180 |
Why?
|
Disease Progression | 12 | 2023 | 13655 | 0.170 |
Why?
|
Molecular Diagnostic Techniques | 3 | 2020 | 614 | 0.170 |
Why?
|
Iodine | 1 | 2022 | 287 | 0.170 |
Why?
|
Deoxycytidine | 1 | 2024 | 888 | 0.170 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2022 | 5426 | 0.170 |
Why?
|
Xeroderma Pigmentosum | 1 | 2019 | 31 | 0.170 |
Why?
|
Transaminases | 1 | 2020 | 199 | 0.170 |
Why?
|
Liver Neoplasms | 3 | 2023 | 4362 | 0.170 |
Why?
|
Radiopharmaceuticals | 4 | 2023 | 2731 | 0.160 |
Why?
|
Papillomavirus E7 Proteins | 1 | 2019 | 110 | 0.160 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 417 | 0.160 |
Why?
|
Antibodies, Monoclonal | 5 | 2016 | 9263 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 218 | 0.160 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2021 | 3665 | 0.160 |
Why?
|
Retrospective Studies | 21 | 2024 | 81834 | 0.160 |
Why?
|
Proto-Oncogene Proteins | 3 | 2023 | 4534 | 0.160 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2020 | 330 | 0.150 |
Why?
|
Oximes | 2 | 2022 | 304 | 0.150 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 876 | 0.150 |
Why?
|
Tretinoin | 1 | 2021 | 525 | 0.150 |
Why?
|
Triazines | 1 | 2020 | 312 | 0.150 |
Why?
|
Young Adult | 14 | 2024 | 60045 | 0.150 |
Why?
|
Paclitaxel | 7 | 2016 | 1737 | 0.150 |
Why?
|
Survival Analysis | 6 | 2021 | 10125 | 0.150 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2018 | 3550 | 0.150 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2020 | 637 | 0.140 |
Why?
|
Bone Neoplasms | 2 | 2022 | 2562 | 0.140 |
Why?
|
DNA, Mitochondrial | 2 | 2023 | 871 | 0.140 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1727 | 0.140 |
Why?
|
Tracheotomy | 1 | 2018 | 168 | 0.140 |
Why?
|
Radiation Oncology | 1 | 2023 | 573 | 0.140 |
Why?
|
Biopsy, Fine-Needle | 3 | 2020 | 1131 | 0.130 |
Why?
|
Activin Receptors, Type II | 1 | 2016 | 123 | 0.130 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2023 | 1628 | 0.130 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 582 | 0.120 |
Why?
|
Prognosis | 14 | 2023 | 30028 | 0.120 |
Why?
|
ras Proteins | 2 | 2020 | 1058 | 0.120 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2019 | 4642 | 0.120 |
Why?
|
Anemia | 1 | 2024 | 1521 | 0.120 |
Why?
|
Cranial Irradiation | 1 | 2017 | 395 | 0.120 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2023 | 2048 | 0.120 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2016 | 285 | 0.120 |
Why?
|
Oncogenes | 1 | 2020 | 1235 | 0.120 |
Why?
|
Blood Pressure Determination | 1 | 2018 | 646 | 0.110 |
Why?
|
Neoplasms, Experimental | 1 | 2019 | 1232 | 0.110 |
Why?
|
Human papillomavirus 16 | 1 | 2016 | 269 | 0.110 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 934 | 0.110 |
Why?
|
Proteinuria | 1 | 2017 | 613 | 0.110 |
Why?
|
Trypsin Inhibitor, Bowman-Birk Soybean | 1 | 2013 | 3 | 0.110 |
Why?
|
Placebos | 1 | 2018 | 1668 | 0.110 |
Why?
|
Time Factors | 8 | 2021 | 40271 | 0.110 |
Why?
|
Trypsin Inhibitors | 1 | 2013 | 34 | 0.110 |
Why?
|
Recovery of Function | 1 | 2024 | 2994 | 0.110 |
Why?
|
Protein Kinases | 1 | 2020 | 1608 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2013 | 10784 | 0.110 |
Why?
|
Leukoplakia, Oral | 1 | 2013 | 79 | 0.100 |
Why?
|
Whole Body Imaging | 1 | 2014 | 285 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2014 | 906 | 0.100 |
Why?
|
Exanthema | 1 | 2017 | 504 | 0.100 |
Why?
|
Cranial Nerve Diseases | 1 | 2012 | 111 | 0.100 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 482 | 0.100 |
Why?
|
Immunotherapy, Adoptive | 2 | 2024 | 1505 | 0.100 |
Why?
|
Ischemic Attack, Transient | 1 | 2017 | 878 | 0.100 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1781 | 0.100 |
Why?
|
Skull Neoplasms | 1 | 2012 | 173 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2021 | 2884 | 0.100 |
Why?
|
Gallbladder | 1 | 2013 | 308 | 0.100 |
Why?
|
Fluorouracil | 7 | 2016 | 1656 | 0.090 |
Why?
|
Deglutition Disorders | 2 | 2008 | 637 | 0.090 |
Why?
|
Lymphatic Diseases | 1 | 2013 | 320 | 0.090 |
Why?
|
Capsid Proteins | 1 | 2014 | 469 | 0.090 |
Why?
|
Paralysis | 1 | 2012 | 250 | 0.090 |
Why?
|
Sarcoma | 1 | 2022 | 1806 | 0.090 |
Why?
|
Diagnosis, Differential | 3 | 2024 | 13026 | 0.090 |
Why?
|
Genotype | 4 | 2014 | 13047 | 0.090 |
Why?
|
Drug Administration Schedule | 4 | 2020 | 4861 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2023 | 2331 | 0.090 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2024 | 616 | 0.090 |
Why?
|
Oncogene Proteins | 1 | 2014 | 718 | 0.090 |
Why?
|
Hedgehog Proteins | 1 | 2014 | 770 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2016 | 647 | 0.090 |
Why?
|
Quality of Life | 6 | 2024 | 13497 | 0.080 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2010 | 101 | 0.080 |
Why?
|
Fatigue | 1 | 2017 | 1556 | 0.080 |
Why?
|
Opportunistic Infections | 1 | 2012 | 376 | 0.080 |
Why?
|
Thyrotropin | 1 | 2013 | 834 | 0.080 |
Why?
|
Gene Expression Profiling | 3 | 2021 | 9507 | 0.080 |
Why?
|
Immunotherapy | 2 | 2024 | 4728 | 0.080 |
Why?
|
Gene Expression | 2 | 2019 | 7605 | 0.080 |
Why?
|
Hypopharyngeal Neoplasms | 1 | 2009 | 52 | 0.080 |
Why?
|
Treatment Failure | 1 | 2015 | 2656 | 0.080 |
Why?
|
Amifostine | 2 | 2009 | 40 | 0.080 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 130 | 0.080 |
Why?
|
Recombinant Fusion Proteins | 2 | 2016 | 3735 | 0.080 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2019 | 3108 | 0.080 |
Why?
|
Tumor Microenvironment | 2 | 2019 | 3939 | 0.080 |
Why?
|
Retreatment | 3 | 2017 | 601 | 0.080 |
Why?
|
Antihypertensive Agents | 1 | 2018 | 2028 | 0.080 |
Why?
|
Esophageal Stenosis | 2 | 2010 | 197 | 0.080 |
Why?
|
Neck | 1 | 2013 | 736 | 0.080 |
Why?
|
Angiogenesis Inhibitors | 3 | 2016 | 2062 | 0.080 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2009 | 158 | 0.080 |
Why?
|
Neck Dissection | 2 | 2006 | 201 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2012 | 1840 | 0.070 |
Why?
|
Carbazoles | 2 | 2019 | 221 | 0.070 |
Why?
|
Biological Therapy | 1 | 2008 | 140 | 0.070 |
Why?
|
Tonsillar Neoplasms | 1 | 2007 | 50 | 0.070 |
Why?
|
Lymphatic Metastasis | 4 | 2024 | 2930 | 0.070 |
Why?
|
Gestational Age | 1 | 2016 | 3615 | 0.070 |
Why?
|
Relative Biological Effectiveness | 1 | 2008 | 314 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 10358 | 0.070 |
Why?
|
Otorhinolaryngologic Neoplasms | 1 | 2006 | 26 | 0.070 |
Why?
|
Ki-67 Antigen | 1 | 2008 | 631 | 0.070 |
Why?
|
Technology, Pharmaceutical | 1 | 2006 | 84 | 0.070 |
Why?
|
Adolescent | 6 | 2022 | 89168 | 0.070 |
Why?
|
Cyclooxygenase 2 | 1 | 2008 | 599 | 0.060 |
Why?
|
Dinoprostone | 1 | 2008 | 597 | 0.060 |
Why?
|
Brain | 1 | 2012 | 27438 | 0.060 |
Why?
|
DNA Damage | 1 | 2015 | 2461 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2014 | 2465 | 0.060 |
Why?
|
Meta-Analysis as Topic | 2 | 2008 | 1364 | 0.060 |
Why?
|
Hypopharynx | 1 | 2004 | 53 | 0.060 |
Why?
|
Radiotherapy, Conformal | 1 | 2008 | 549 | 0.060 |
Why?
|
Incidence | 3 | 2019 | 21552 | 0.060 |
Why?
|
Xerostomia | 3 | 2010 | 94 | 0.060 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2024 | 196 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 3 | 2024 | 20762 | 0.060 |
Why?
|
Lipid Peroxides | 1 | 2023 | 74 | 0.050 |
Why?
|
Radiation-Protective Agents | 1 | 2003 | 88 | 0.050 |
Why?
|
Melanoma | 1 | 2022 | 5740 | 0.050 |
Why?
|
Larynx | 1 | 2008 | 492 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2017 | 3543 | 0.050 |
Why?
|
Oxyphil Cells | 1 | 2023 | 56 | 0.050 |
Why?
|
Tropomyosin | 1 | 2023 | 106 | 0.050 |
Why?
|
Oligonucleotides | 3 | 2013 | 564 | 0.050 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2024 | 259 | 0.050 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2024 | 213 | 0.050 |
Why?
|
Fermentation | 1 | 2023 | 142 | 0.050 |
Why?
|
Radiation Injuries | 2 | 2008 | 1205 | 0.050 |
Why?
|
Gastroscopy | 1 | 2004 | 213 | 0.050 |
Why?
|
Administration, Oral | 2 | 2014 | 4041 | 0.050 |
Why?
|
Pain | 2 | 2022 | 5096 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2017 | 5308 | 0.050 |
Why?
|
Neoplasms, Second Primary | 1 | 2010 | 1062 | 0.050 |
Why?
|
Macrophages | 1 | 2017 | 5797 | 0.050 |
Why?
|
Brain Neoplasms | 2 | 2018 | 9182 | 0.050 |
Why?
|
Pilot Projects | 3 | 2017 | 8730 | 0.050 |
Why?
|
Immunoenzyme Techniques | 2 | 2016 | 1706 | 0.050 |
Why?
|
Cell Line, Tumor | 4 | 2020 | 17149 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 1409 | 0.050 |
Why?
|
Radiotherapy Dosage | 4 | 2010 | 2925 | 0.050 |
Why?
|
Interleukin-8 | 1 | 2005 | 705 | 0.050 |
Why?
|
Immunohistochemistry | 3 | 2021 | 11138 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2013 | 3472 | 0.050 |
Why?
|
Biomedical Research | 1 | 2017 | 3463 | 0.050 |
Why?
|
Thyroid Function Tests | 1 | 2022 | 289 | 0.050 |
Why?
|
Remission Induction | 2 | 2006 | 2408 | 0.050 |
Why?
|
Massachusetts | 1 | 2014 | 8908 | 0.050 |
Why?
|
Algorithms | 1 | 2021 | 14158 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6978 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2021 | 314 | 0.040 |
Why?
|
Signal Transduction | 4 | 2019 | 23638 | 0.040 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 1994 | 388 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2013 | 5532 | 0.040 |
Why?
|
Databases, Factual | 3 | 2021 | 8081 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2018 | 3619 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2019 | 5891 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2022 | 387 | 0.040 |
Why?
|
Ultrasonography | 1 | 2013 | 5995 | 0.040 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2021 | 350 | 0.040 |
Why?
|
Patient Compliance | 1 | 2009 | 2696 | 0.040 |
Why?
|
Poly I-C | 1 | 2019 | 111 | 0.040 |
Why?
|
Mental Disorders | 1 | 2019 | 6879 | 0.040 |
Why?
|
Laryngoscopy | 1 | 2004 | 714 | 0.040 |
Why?
|
Phenotype | 2 | 2020 | 16712 | 0.040 |
Why?
|
Mass Screening | 1 | 2014 | 5455 | 0.040 |
Why?
|
Haploidy | 1 | 2018 | 127 | 0.040 |
Why?
|
Risk Assessment | 4 | 2018 | 24311 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2016 | 624 | 0.040 |
Why?
|
Injections, Intramuscular | 1 | 2019 | 557 | 0.040 |
Why?
|
Cohort Studies | 4 | 2020 | 41797 | 0.040 |
Why?
|
Follow-Up Studies | 6 | 2017 | 39430 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 861 | 0.040 |
Why?
|
Annual Reports as Topic | 1 | 2017 | 36 | 0.040 |
Why?
|
Therapeutics | 1 | 2017 | 113 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12561 | 0.030 |
Why?
|
Clonal Anergy | 1 | 2017 | 169 | 0.030 |
Why?
|
International Agencies | 1 | 2017 | 245 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2024 | 21156 | 0.030 |
Why?
|
Cytodiagnosis | 1 | 2020 | 452 | 0.030 |
Why?
|
Pyridones | 1 | 2022 | 819 | 0.030 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2017 | 126 | 0.030 |
Why?
|
Platinum Compounds | 1 | 2017 | 95 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2022 | 864 | 0.030 |
Why?
|
Prospective Studies | 5 | 2024 | 54914 | 0.030 |
Why?
|
Tyrosine | 1 | 2020 | 1428 | 0.030 |
Why?
|
Propensity Score | 1 | 2024 | 1971 | 0.030 |
Why?
|
United States | 6 | 2022 | 73121 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2016 | 26395 | 0.030 |
Why?
|
Societies, Medical | 2 | 2018 | 3955 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2019 | 1355 | 0.030 |
Why?
|
Breast | 1 | 2024 | 1976 | 0.030 |
Why?
|
Drug Approval | 1 | 2022 | 817 | 0.030 |
Why?
|
Amygdala | 1 | 2023 | 1382 | 0.030 |
Why?
|
Animals | 9 | 2020 | 169418 | 0.030 |
Why?
|
Laryngectomy | 2 | 2009 | 245 | 0.030 |
Why?
|
Stroke | 1 | 2017 | 9791 | 0.030 |
Why?
|
DNA, Viral | 1 | 2022 | 2206 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2009 | 727 | 0.030 |
Why?
|
Sulindac | 1 | 2014 | 29 | 0.030 |
Why?
|
Stomatitis | 2 | 2009 | 271 | 0.030 |
Why?
|
Guanine Nucleotide Dissociation Inhibitors | 1 | 1993 | 23 | 0.030 |
Why?
|
Kinetics | 1 | 2022 | 6348 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2022 | 1669 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2019 | 1337 | 0.030 |
Why?
|
Dyspnea | 1 | 2022 | 1352 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2019 | 757 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2019 | 1251 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2019 | 1561 | 0.030 |
Why?
|
Telomerase | 1 | 2018 | 751 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1089 | 0.030 |
Why?
|
Receptor, erbB-2 | 2 | 2015 | 2586 | 0.030 |
Why?
|
Research Support as Topic | 1 | 2017 | 699 | 0.030 |
Why?
|
Biopsy | 1 | 2024 | 6816 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2014 | 551 | 0.030 |
Why?
|
Carcinoembryonic Antigen | 1 | 2013 | 338 | 0.020 |
Why?
|
Glioblastoma | 1 | 2007 | 3523 | 0.020 |
Why?
|
Consensus | 1 | 2022 | 3207 | 0.020 |
Why?
|
Mice | 5 | 2019 | 82045 | 0.020 |
Why?
|
Mice, Nude | 1 | 2018 | 3635 | 0.020 |
Why?
|
Cancer Vaccines | 1 | 2019 | 1044 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 3438 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2019 | 3169 | 0.020 |
Why?
|
DNA Mutational Analysis | 2 | 2016 | 4120 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2017 | 2640 | 0.020 |
Why?
|
Histone Deacetylases | 1 | 2015 | 717 | 0.020 |
Why?
|
Palliative Care | 1 | 2005 | 3644 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2021 | 2987 | 0.020 |
Why?
|
Fungal Proteins | 1 | 1994 | 908 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 2046 | 0.020 |
Why?
|
Ligands | 1 | 2016 | 3281 | 0.020 |
Why?
|
GTP-Binding Proteins | 1 | 1993 | 947 | 0.020 |
Why?
|
Receptors, Somatomedin | 1 | 2008 | 57 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2018 | 6241 | 0.020 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2009 | 179 | 0.020 |
Why?
|
Doxorubicin | 1 | 2015 | 2229 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4586 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2019 | 5495 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1395 | 0.020 |
Why?
|
Gene Amplification | 1 | 2012 | 1091 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2009 | 681 | 0.020 |
Why?
|
Radiotherapy | 1 | 2015 | 1510 | 0.020 |
Why?
|
Organ Specificity | 2 | 2008 | 1972 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8510 | 0.020 |
Why?
|
Viral Matrix Proteins | 1 | 2009 | 193 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2010 | 424 | 0.020 |
Why?
|
Lymphocytes | 1 | 2015 | 2611 | 0.020 |
Why?
|
Vaccination | 1 | 2019 | 3434 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6657 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2008 | 882 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2017 | 5904 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2016 | 2643 | 0.020 |
Why?
|
Health | 1 | 2009 | 399 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5909 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2009 | 1775 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2017 | 4419 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5367 | 0.010 |
Why?
|
Age Factors | 1 | 2021 | 18478 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15460 | 0.010 |
Why?
|
DNA Repair | 1 | 1994 | 2051 | 0.010 |
Why?
|
Cloning, Molecular | 3 | 1994 | 4175 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2016 | 4572 | 0.010 |
Why?
|
Regression Analysis | 1 | 2013 | 6353 | 0.010 |
Why?
|
Risk Factors | 3 | 2018 | 74915 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12096 | 0.010 |
Why?
|
MutS Homolog 2 Protein | 2 | 1994 | 200 | 0.010 |
Why?
|
Genetic Testing | 1 | 2017 | 3586 | 0.010 |
Why?
|
Postoperative Care | 1 | 2010 | 1481 | 0.010 |
Why?
|
Pharyngeal Diseases | 1 | 2004 | 134 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2019 | 19041 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20231 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2019 | 8635 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2019 | 10494 | 0.010 |
Why?
|
Epitopes | 1 | 2009 | 2526 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2017 | 3230 | 0.010 |
Why?
|
Child | 2 | 2021 | 80863 | 0.010 |
Why?
|
Mitosis | 1 | 2007 | 1191 | 0.010 |
Why?
|
Constriction, Pathologic | 1 | 2004 | 1103 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 22365 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2024 | 36840 | 0.010 |
Why?
|
DNA-Binding Proteins | 2 | 1994 | 9623 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2014 | 12813 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2008 | 2067 | 0.010 |
Why?
|
Child, Preschool | 1 | 2021 | 42623 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2008 | 2882 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 18048 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18388 | 0.010 |
Why?
|
Boston | 1 | 2010 | 9361 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2008 | 2238 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2008 | 3463 | 0.010 |
Why?
|
Pedigree | 2 | 1994 | 4545 | 0.010 |
Why?
|
Chromosome Mapping | 2 | 1994 | 4622 | 0.010 |
Why?
|
Transcription Factors | 1 | 2014 | 12174 | 0.010 |
Why?
|
Cytokines | 1 | 2009 | 7449 | 0.010 |
Why?
|
Yolk Sac | 1 | 1993 | 79 | 0.010 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 1994 | 313 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2005 | 3520 | 0.010 |
Why?
|
rac GTP-Binding Proteins | 1 | 1993 | 163 | 0.010 |
Why?
|
cdc42 GTP-Binding Protein | 1 | 1993 | 188 | 0.010 |
Why?
|
Frameshift Mutation | 1 | 1994 | 393 | 0.010 |
Why?
|
Apoptosis | 1 | 2008 | 9526 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 1994 | 13452 | 0.010 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 1993 | 431 | 0.010 |
Why?
|
Introns | 1 | 1994 | 970 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 1994 | 17647 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2009 | 22293 | 0.010 |
Why?
|
DNA Primers | 1 | 1994 | 2826 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1993 | 1992 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2008 | 15965 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1993 | 2751 | 0.010 |
Why?
|
Sequence Alignment | 1 | 1993 | 2184 | 0.010 |
Why?
|
Genetic Linkage | 1 | 1994 | 2342 | 0.010 |
Why?
|
Exons | 1 | 1994 | 2392 | 0.000 |
Why?
|
DNA, Neoplasm | 1 | 1994 | 1749 | 0.000 |
Why?
|
Diet | 1 | 2006 | 8098 | 0.000 |
Why?
|
Biological Evolution | 1 | 1994 | 1081 | 0.000 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1993 | 1557 | 0.000 |
Why?
|
Base Sequence | 1 | 1994 | 12428 | 0.000 |
Why?
|
DNA | 1 | 1994 | 7213 | 0.000 |
Why?
|